Janssen Biotech, Inc. Drug Patent Portfolio

Janssen Biotech, Inc. owns 1 purple book drug protected by 6 US patents Given below is the list of Janssen Biotech, Inc.'s drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10961307 Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody 24 Sep, 2039
Active
US9217168 Methods of cell culture 14 Mar, 2033
Active
US9663810 Methods of cell culture 14 Mar, 2033
Active
US8852889 Cell culture process 06 Jul, 2032
Active
US9475858 Cell culture process 06 Jul, 2032
Active
US6902734 Anti-IL-12 antibodies and compositions thereof 25 Sep, 2023
Active


Janssen Biotech, Inc.'s Family Patents


Family Patents



Janssen Biotech, Inc. Drug List

Given below is the complete list of Janssen Biotech, Inc.'s drugs and the patents protecting them.


1. Stelara

Stelara is protected by 6 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10961307 Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody 24 Sep, 2039
(14 years from now)
Active
US9217168 Methods of cell culture 14 Mar, 2033
(8 years from now)
Active
US9663810 Methods of cell culture 14 Mar, 2033
(8 years from now)
Active
US8852889 Cell culture process 06 Jul, 2032
(7 years from now)
Active
US9475858 Cell culture process 06 Jul, 2032
(7 years from now)
Active
US6902734 Anti-IL-12 antibodies and compositions thereof 25 Sep, 2023
(1 year, 2 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stelara's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List